Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs

被引：24

作者：

Hermann, Matthias ^{[1
]}

Ruschitzka, Frank ^{[1
]}

机构：

[1] Univ Zurich Hosp, Cardiovas Ctr, CH-8091 Zurich, Switzerland

来源：

ANNALS OF MEDICINE | 2007年 / 39卷 / 01期

关键词：

cardiovascular risk; coxibs; hypertension; NSAIDs;

D O I：

10.1080/07853890601073445

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since selective cyclooxygenase-2 inhibitors (coxibs) entered the market, there has been concern about the cardiovascular safety of coxibs. In addition, recent data suggest that classical non-steroidal anti-inflammatory drugs (NSAIDs) have a similar cardiovascular risk. Importantly, all of the clinical trials with NSAIDs and coxibs so far were not purpose-designed to specifically and prospectively address cardiovascular safety and were clearly underpowered to detect any meaningful differences. In this current uncertainty about safety of NSAIDs and coxibs, the definitive answer as to the net effect of coxibs and NSAIDs on cardiovascular events can only be provided by well designed adequately powered, long-term clinical trials, which is now under way.

引用

页码：18 / 27

页数：10

共 48 条

[1] Use of first- and second-generation cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction
Andersohn, F
Suissa, S
Garbe, E
[J]. CIRCULATION, 2006, 113 (16) : 1950 - 1957
[2] Celecoxib for the prevention of colorectal adenomatous polyps
Arber, Nadir
Eagle, Craig J.
Spicak, Julius
Racz, Istvan
Dite, Petr
Hajer, Jan
Zavoral, Miroslav
Lechuga, Maria J.
Gerletti, Paola
Tang, Jie
Rosenstein, Rebecca B.
Macdonald, Katie
Bhadra, Pritha
Fowler, Robert
Wittes, Janet
Zauber, Ann G.
Solomon, Scott D.
Levin, Bernard
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) : 885 - 895
[3] Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure
Aw, TJ
Haas, SJ
Liew, D
Krum, H
[J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) : 490 - 496
[4] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
Bombardier, C
Laine, L
Reicin, A
Shapiro, D
Burgos-Vargas, R
Davis, B
Day, R
Ferraz, MB
Hawkey, CJ
Hochberg, MC
Kvien, TK
Schnitzer, TJ
Weaver, A
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
[5] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
Bresalier, RS
Sandler, RS
Quan, H
Bolognese, JA
Oxenius, B
Horgan, K
Lines, C
Riddell, R
Morton, D
Lanas, A
Konstam, MA
Baron, JA
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
[6] Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis
Caldwell, B
Aldington, S
Weatherall, M
Shirtcliffe, P
Beasley, R
[J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2006, 99 (03) : 132 - 140
[7] Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events
Chan, AT
Manson, JE
Albert, CM
Chae, CU
Rexrode, KM
Curhan, GC
Rimm, EB
Willett, WC
Fuchs, CS
[J]. CIRCULATION, 2006, 113 (12) : 1578 - 1587
[8] Selective COX-2 inhibition improves endothelial function in coronary artery disease
Chenevard, R
Hürlimann, D
Béchir, M
Enseleit, F
Spieker, L
Hermann, M
Riesen, W
Gay, S
Gay, RE
Neidhart, M
Michel, B
Lüscher, TF
Noll, G
Ruschitzka, F
[J]. CIRCULATION, 2003, 107 (03) : 405 - 409
[9] Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials
Curtis, SP
Ng, J
Yu, QF
Shingo, S
Bergman, G
McCormick, CL
Reicin, AS
[J]. CLINICAL THERAPEUTICS, 2004, 26 (01) : 70 - 83
[10] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
Farkouh, ME
Kirshner, H
Harrington, RA
Ruland, S
Verheugt, FW
Schnitzer, T
Burmester, GR
Mysler, E
Hochberg, MC
Doherty, M
Ehrsam, E
Gitton, X
Krammer, G
Mellein, B
Gimona, A
Matchaba, P
Hawkey, CJ
Chesebro, JH
[J]. LANCET, 2004, 364 (9435) : 675 - 684

← 1 2 3 4 5 →